Top > Search of International Patents > ACUTE RENAL FAILURE-SPECIFIC BIOMARKER, ACUTE RENAL FAILURE DIAGNOSIS METHOD, ACUTE RENAL FAILURE TEST KIT, ANIMAL TREATMENT METHOD AND ACUTE RENAL FAILURE MEDICATION

ACUTE RENAL FAILURE-SPECIFIC BIOMARKER, ACUTE RENAL FAILURE DIAGNOSIS METHOD, ACUTE RENAL FAILURE TEST KIT, ANIMAL TREATMENT METHOD AND ACUTE RENAL FAILURE MEDICATION

Foreign code F210010297
File No. S2018-1076-C0
Posted date Jan 28, 2021
Country WIPO
International application number 2019JP039227
International publication number WO 2020071518
Date of international filing Oct 4, 2019
Date of international publication Apr 9, 2020
Priority data
  • P2018-188746 (Oct 4, 2018) JP
Title ACUTE RENAL FAILURE-SPECIFIC BIOMARKER, ACUTE RENAL FAILURE DIAGNOSIS METHOD, ACUTE RENAL FAILURE TEST KIT, ANIMAL TREATMENT METHOD AND ACUTE RENAL FAILURE MEDICATION
Abstract Provided is a biomarker capable of specifically diagnosing acute renal failure. The acute renal failure-specific biomarker is miRNA which is primarily present in blood. The miRNA is miRNA-5100. Furthermore, it is possible to use this miRNA-5100 as a method for diagnosing acute renal failure. When making a diagnosis, acute renal failure is diagnosed when miRNA-5100 expression in the blood decreases. As a kit for testing for acute renal failure, it is possible to include a reagent which measures miRNA-5100.
Outline of related art and contending technology BACKGROUND ART
Acute renal failure (Acute kidney injury, AKI) is, the infectious disease, medication, such as after surgery and acute renal dysfunction occurs, are largely responsible for the prognosis of a patient's life. Acute renal failure (AKI) is, in a short period of several hours to several days is reduced renal function rapidly in a disease. Urine excretion of waste products from unavailable, or to overflow. Dialysis and may be required.
Conventional, acute renal failure (Kidney Disease: Improving Global Outcomes) KDIGO diagnostic guidelines are provided. This KDIGO classification, urine and serum creatinine Acute renal failure is increased based on the decrease in the amount has been diagnosed.
Specifically, (KDIGO for acute renal failure diagnosis guideline, AKI (stage) of the classification stage, defined by any of the following: one or more serum creatinine value within 1. 48 to 0.3mg/dl to increase the serum creatinine value within the previous 2. has been found that 7 or 1.5 times or more the expected base value if there is an increase in the urine over a period of time 3. 6 0.5ml/kg/amount is reduced to
However, this reference has already been missed in the timing of therapeutic intervention in many cases. For this reason, the development of a biomarker for acute renal failure has been desired.
Incidentally, in recent years, a variety (microRNA, micro RNA) miRNA involved in the disease, early diagnosis of disease is effective as a biomarker has been reported. Referring to Patent Document 1, as an example of a conventional biomarker, chronic diabetic status of the indication of the miRNA is described.
Scope of claims (In Japanese)[請求項1]
 急性腎障害特異的バイオマーカーであって、
 miRNA-5100である
 ことを特徴とする急性腎障害特異的バイオマーカー。

[請求項2]
 請求項1に記載の急性腎障害特異的バイオマーカーを用いる
 ことを特徴とする急性腎障害の診断方法。

[請求項3]
 前記miRNA-5100の発現が低下している場合、急性腎障害と診断する
 ことを特徴とする請求項2に記載の急性腎障害の診断方法。

[請求項4]
 miRNA-5100を測定する試薬を含む
 ことを特徴とする急性腎障害の検査用キット。

[請求項5]
 ヒト以外の動物の治療方法であって、
 miRNA-5100の機能活性を調整する
 ことを特徴とする動物治療方法。

[請求項6]
 miRNA-5100の機能活性調整剤を含む
 ことを特徴とする急性腎障害用医薬。

[請求項7]
 前記機能活性調整剤は、
 前記miRNA-5100の機能活性亢進剤を含む
 ことを特徴とする請求項6に記載の急性腎障害用医薬。

[請求項8]
 前記機能活性亢進剤は、前記miRNA-5100に対応したmiRNAミミックである
 ことを特徴とする請求項7に記載の急性腎障害用医薬。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • JICHI MEDICAL UNIVERSITY
  • Inventor
  • MORISHITA, Yoshiyuki
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close